The independent source for health policy research, polling, and news.
941 - 960 of 1,304 Results
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Anna Edney of Bloomberg News, Margot Sanger-Katz of The New York Times and Kimberly Leonard of the Washington Examiner talk about the latest Trump administration efforts to address high drug prices, what’s next for short-term health insurance plans and insider trading charges against a New York GOP congressman.
Inspector general identifies possible problems in nearly 23 percent of pharmacies that bill Medicare for blended creams, gels and lotions.
Rep. Chris Collins talked one time too many, according to federal prosecutors who on Wednesday charged him with violating insider trading laws.
The New York congressman was a major investor in an Australian biotechnology firm and prosecutors allege that he tipped off his son and others to sell stock shortly before the company reported poor results in its drug testing.
The number of diabetes drug prescriptions filled for low-income people enrolled in Medicaid rose sharply in states that expanded eligibility for the program under the Affordable Care Act, according to a new study.
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
Gabapentin, a medication approved to help patients with nerve pain or epilepsy, is being abused by people addicted to opioids to help prolong their high or stave off withdrawal from other drugs. Kaiser Health News reporter Carmen Heredia Rodriguez talks about the problem during a wide-ranging health discussion on the NPR program "On Point."
Fentanyl and other painkillers marketed as safer than Purdue Pharma’s blockbuster drug left their own trail of overdose deaths.
States are passing laws that limit a doctor's ability to prescribe opioids. Doctors and patients alike are wrestling with what that means in cases of chronic pain.
The Trump administration signals it is willing to consider such a move if it is carefully tailored to focus solely on specific situations where a high-priced drug is made by one company.
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
Grants by top pharma group to lightly regulated, politically active nonprofits dwarf its conventional campaign spending.
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Anna Edney of Bloomberg News, Alice Ollstein of Talking Points Memo and Kimberly Leonard of the Washington Examiner talk about the new push on health legislation by Republicans in the House, as well as developments on Medicaid work requirements, drug prices and the fate of children separated from their parents at the U.S.-Mexican border. Plus, for extra credit, the panelists offer their favorite health stories of the week.
Several major drugmakers vow to contain drug prices, but similar pledges since the 1990s have not had much impact.
Did OxyContin maker admit opioids can be dangerous even when patients take them as prescribed — then walk it back?
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico, and Erin Mershon of Stat News discuss a series of health policy court decisions on everything from prescription drug discounts to soda taxes. Plus, Rovner, interviews health care futurist and consultant Jeff Goldsmith.
Some state Medicaid programs are not paying for the procedures, and Medicare’s complicated payment rates have hospitals concerned that it will not cover all the costs.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
© 2026 KFF